Prognostic value of skin/pectoral muscle invasion for male breast cancer: a single-center retrospective analysis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHOU Chen ¹ , ZHANG Xue ² , TAN Qiuwen ¹ , HE Miao ¹ , LÜ Qing ¹ ,  CHEN Yujuan ¹

1. Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
2. Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;

Corresponding author：

CHEN Yujuan, Email: 33029714@qq.com

Keywords：

male breast cancer; skin or pectoral muscle invasion; clicopathological feature; prognosis

DOI：

10.7507/1007-9424.202205054

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the relationship between skin/pectoral muscle invasion and the prognosis of male breast cancer. Methods Clinical data and follow-up information of 79 male breast cancer patients who received treatment between September 2008 to April 2020 in West China Hospital were retrospectively reviewed, to analyze the clinicopathological features of male breast cancer and prognostic value of skin/pectoral muscle invasion. Results Among 79 male breast cancer patients, a total of 23 patients (29.1%) were with skin/pectoral muscle invasion at diagnosis. All the patients were followed up, with a median follow-up period of 63.3 months (1.0–204.5 months). Within follow-up period, 8 patients (10.1%) suffered from relapse, 19 patients (24.7%, 19/77) suffered from metastasis, and 4 patients (5.1%) died. Multivariate Cox proportional risk regression model suggested that patients with skin/pectoral muscle invaded had poor disease free survival [RR=4.48, 95%CI (1.08, 18.52), P=0.038]. Conclusions Skinor pectoral muscle invasion might be a valuable prognostic factor for male breast cancer patients. However, limited by sample size, the conclusion should be proved by further high-level studies.

Citation： ZHOU Chen, ZHANG Xue, TAN Qiuwen, HE Miao, LÜ Qing, CHEN Yujuan. Prognostic value of skin/pectoral muscle invasion for male breast cancer: a single-center retrospective analysis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2022, 29(11): 1468-1474. doi: 10.7507/1007-9424.202205054 Copy

1.	Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline. J Clin Oncol, 2020, 38(16): 1849-1863.
2.	Elimimian EB, Elson L, Li H, et al. Male breast cancer: A comparative analysis from the national cancer database. World J Mens Health, 2021, 39(3): 506-515.
3.	Donegan WL, Redlich PN, Lang PJ, et al. Carcinoma of the breast in males: a multiinstitutional survey. Cancer, 1998, 83(3): 498-509.
4.	Ottini L. Male breast cancer: a rare disease that might uncover underlying pathways of breast cancer. Nat Rev Cancer, 2014, 14(10): 643. doi: 10.1038/nrc3806.
5.	Abdelwahab Yousef AJ. Male breast cancer: Epidemiology and risk factors. Semin Oncol, 2017, 44(4): 267-272.
6.	Contractor KB, Kaur K, Rodrigues GS, et al. Male breast cancer: is the scenario changing. World J Surg Oncol, 2008, 6: 58. doi: 10.1186/1477-7819-6-58.
7.	Liu N, Johnson KJ, Ma CX. Male breast cancer: An updated surveillance, epidemiology, and end results data analysis. Clin Breast Cancer, 2018, 18(5): e997-e1002.
8.	Fentiman IS. The endocrinology of male breast cancer. Endocr Relat Cancer, 2018, 25(6): R365-R373.
9.	周斌, 季科, 辛灵, 等. 美国肿瘤联合会乳腺癌分期系统(第8版)更新内容介绍及解读. 中国实用外科杂志, 2017, 37(1): 10-14.
10.	Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual. 8th ed. New York: Springer. 2017.
11.	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范 (2021年版). 中国癌症杂志, 2021, 31(10): 954-1040.
12.	Khan NAJ, Tirona M. An updated review of epidemiology, risk factors, and management of male breast cancer. Med Oncol, 2021, 38(4): 39. doi: 10.1007/s12032-021-01486-x.
13.	Giordano SH. Breast cancer in men. N Engl J Med, 2018, 378(24): 2311-2320.
14.	Konduri S, Singh M, Bobustuc G, et al. Epidemiology of male breast cancer. Breast, 2020, 54: 8-14.
15.	Miao H, Verkooijen HM, Chia KS, et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol, 2011, 29(33): 4381-4386.
16.	吴雅媛, 王彤, 刘红. 男性乳腺癌125例患者的临床病理特征与生存分析. 肿瘤, 2012, 32(10): 805-810.
17.	罗祖强, 庄志泉, 董为松, 等. p57KIP2、cyclinD1、cyclinE在男性乳腺癌组织中的表达及其临床意义. 中国肿瘤临床, 2018, 45(3): 126-130.
18.	赵宝国, 代文杰. 男性乳腺癌的诊断和治疗进展. 中国普外基础与临床杂志, 2015, 22(6): 759-762.
19.	徐斌, 邵营波, 张莹, 等. 男性乳腺癌患者49例预后因素分析. 中华肿瘤防治杂志, 2015, 22(13): 1037-1041.
20.	丁颖, 龙汉安, 叶入裴, 等. 男性乳腺癌与女性乳腺癌临床病理学特征对比分析. 西南医科大学学报, 2019, 42(1): 40-43.
21.	Chen Z, Xu L, Shi W, et al. Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990-2017. Breast Cancer Res Treat, 2020, 180(2): 481-490.
22.	Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG international male breast cancer program. Ann Oncol, 2018, 29(2): 405-417.
23.	Mangone L, Ferrari F, Mancuso P, et al. Epidemiology and biological characteristics of male breast cancer in Italy. Breast Cancer, 2020, 27(4): 724-731.
24.	Chavez-Macgregor M, Clarke CA, Lichtensztajn D, et al. Male breast cancer according to tumor subtype and race: a population-based study. Cancer, 2013, 119(9): 1611-1617.
25.	Leone JP, Leone J, Zwenger AO, et al. Locoregional treatment and overall survival of men with T1a, b, cN0M0 breast cancer: A population-based study. Eur J Cancer, 2017, 71: 7-14.
26.	Eggemann H, Ignatov A, Smith BJ, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat, 2013, 137(2): 465-470.
27.	Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol, 2016, 34(19): 2221-2231.

1. Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline. J Clin Oncol, 2020, 38(16): 1849-1863.
2. Elimimian EB, Elson L, Li H, et al. Male breast cancer: A comparative analysis from the national cancer database. World J Mens Health, 2021, 39(3): 506-515.
3. Donegan WL, Redlich PN, Lang PJ, et al. Carcinoma of the breast in males: a multiinstitutional survey. Cancer, 1998, 83(3): 498-509.
4. Ottini L. Male breast cancer: a rare disease that might uncover underlying pathways of breast cancer. Nat Rev Cancer, 2014, 14(10): 643. doi: 10.1038/nrc3806.
5. Abdelwahab Yousef AJ. Male breast cancer: Epidemiology and risk factors. Semin Oncol, 2017, 44(4): 267-272.
6. Contractor KB, Kaur K, Rodrigues GS, et al. Male breast cancer: is the scenario changing. World J Surg Oncol, 2008, 6: 58. doi: 10.1186/1477-7819-6-58.
7. Liu N, Johnson KJ, Ma CX. Male breast cancer: An updated surveillance, epidemiology, and end results data analysis. Clin Breast Cancer, 2018, 18(5): e997-e1002.
8. Fentiman IS. The endocrinology of male breast cancer. Endocr Relat Cancer, 2018, 25(6): R365-R373.
9. 周斌, 季科, 辛灵, 等. 美国肿瘤联合会乳腺癌分期系统(第8版)更新内容介绍及解读. 中国实用外科杂志, 2017, 37(1): 10-14.
10. Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual. 8th ed. New York: Springer. 2017.
11. 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范 (2021年版). 中国癌症杂志, 2021, 31(10): 954-1040.
12. Khan NAJ, Tirona M. An updated review of epidemiology, risk factors, and management of male breast cancer. Med Oncol, 2021, 38(4): 39. doi: 10.1007/s12032-021-01486-x.
13. Giordano SH. Breast cancer in men. N Engl J Med, 2018, 378(24): 2311-2320.
14. Konduri S, Singh M, Bobustuc G, et al. Epidemiology of male breast cancer. Breast, 2020, 54: 8-14.
15. Miao H, Verkooijen HM, Chia KS, et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol, 2011, 29(33): 4381-4386.
16. 吴雅媛, 王彤, 刘红. 男性乳腺癌125例患者的临床病理特征与生存分析. 肿瘤, 2012, 32(10): 805-810.
17. 罗祖强, 庄志泉, 董为松, 等. p57KIP2、cyclinD1、cyclinE在男性乳腺癌组织中的表达及其临床意义. 中国肿瘤临床, 2018, 45(3): 126-130.
18. 赵宝国, 代文杰. 男性乳腺癌的诊断和治疗进展. 中国普外基础与临床杂志, 2015, 22(6): 759-762.
19. 徐斌, 邵营波, 张莹, 等. 男性乳腺癌患者49例预后因素分析. 中华肿瘤防治杂志, 2015, 22(13): 1037-1041.
20. 丁颖, 龙汉安, 叶入裴, 等. 男性乳腺癌与女性乳腺癌临床病理学特征对比分析. 西南医科大学学报, 2019, 42(1): 40-43.
21. Chen Z, Xu L, Shi W, et al. Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990-2017. Breast Cancer Res Treat, 2020, 180(2): 481-490.
22. Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG international male breast cancer program. Ann Oncol, 2018, 29(2): 405-417.
23. Mangone L, Ferrari F, Mancuso P, et al. Epidemiology and biological characteristics of male breast cancer in Italy. Breast Cancer, 2020, 27(4): 724-731.
24. Chavez-Macgregor M, Clarke CA, Lichtensztajn D, et al. Male breast cancer according to tumor subtype and race: a population-based study. Cancer, 2013, 119(9): 1611-1617.
25. Leone JP, Leone J, Zwenger AO, et al. Locoregional treatment and overall survival of men with T1a, b, cN0M0 breast cancer: A population-based study. Eur J Cancer, 2017, 71: 7-14.
26. Eggemann H, Ignatov A, Smith BJ, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat, 2013, 137(2): 465-470.
27. Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol, 2016, 34(19): 2221-2231.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Prognostic value of skin/pectoral muscle invasion for male breast cancer: a single-center retrospective analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content